TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04665206: Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor: Vivace Therapeutics, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 434 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT04665206 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04665206 Rescue Dossier →